Alfuzosin

Alfuzosin

Clinical data
Pronunciation	al-FYOO-zoe-sin
Trade names	Uroxatral, others
AHFS/Drugs.com	Monograph
MedlinePlus	a64002
Pregnancy category	AU: B2
Routes of administration	By mouth (tablets)
ATC code	G04CA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	49%
Protein binding	82–90%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Feces (69%) and Urine (24%)
Identifiers
IUPAC name N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
CAS Number	81403-80-7 Y
PubChem CID	2092
IUPHAR/BPS	7109
DrugBank	DB00346 Y
ChemSpider	2008 Y
UNII	90347YTW5F
KEGG	D07124 Y
ChEBI	CHEBI:51141 Y
ChEMBL	ChEMBL709 Y
CompTox Dashboard (EPA)	DTXSID6048549
ECHA InfoCard	100.108.671
Chemical and physical data
Formula	C19H27N5O4
Molar mass	389.449 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
InChI InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) Y Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N Y
(verify)

Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the α₁ blocker class. As an antagonist of the α₁ adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural. Alfuzosin was approved by the U.S. FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, fatigue, and abdominal disturbances.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

• Uroxatral (alfuzosin HCl) Extended-Release Tablets Prescribing Information
• Alfuzosin (General information from the NIH)